Project description:Interventions: Control group:nothing;Colon adeno group:nothing;Colon cancer group:nothing
Primary outcome(s): Intestinal microbial composition
Study Design: Case-Control study
Project description:miRNA expression profiles of CLL cells and normal B cells (NBC) treated for 18 hr with 10 ng/ml IL-4, compared with culture with nothing (Ctrl) and the basal (Pre) samples.
Project description:Measurement of mRNA abundance from the following cells lines (red) versus universal mouse reference RNA (green). Wildtype v-Abl transformed pre-B cells were treated for 12 hours with 2.5 uM imatinib mesylate, 10ng/mL rapamycin or nothing. Compound Based Treatment: wildtype v-Abl transformed pre-B cells were treated with imatinib mesylate (IMA), rapamycin (RAP) or nothing (NONE)
Project description:Measurement of mRNA abundance from the following cells lines (red) versus universal mouse reference RNA (green). Wildtype v-Abl transformed pre-B cells were treated for 12 hours with 2.5 uM imatinib mesylate, 10ng/mL rapamycin or nothing. Compound Based Treatment: wildtype v-Abl transformed pre-B cells were treated with imatinib mesylate (IMA), rapamycin (RAP) or nothing (NONE) compound_treatment_design
Project description:Identifying the HDAC6 targeting DARPin F10 interacting protein in human cells. Proteins are expressed as GFP fused protein and captured by GFP-trap beads. DARPin CTR is a control DARPin that binds to nothing.
Project description:We fed hypercholesterolemic mice high fat diet containing either ticagrelor, clopidogrel, or nothing (control) for 16 weeks, isolated the liver, extracted RNA, and subjected the RNA to RNA-Seq using NGS.
Project description:We fed hypercholesterolemic mice high fat diet containing either ticagrelor, clopidogrel, or nothing (control) for 16 weeks, isolated the aortae, extracted RNA, and subjected the RNA to RNA-Seq using NGS.
